Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Alzheimers Dis ; 98(2): 715-727, 2024.
Article in English | MEDLINE | ID: mdl-38427472

ABSTRACT

Background: Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) are major neurodegenerative conditions with tau pathology in common but distinct symptoms-AD involves cognitive decline while PSP affects balance and eye movement. Progranulin (PGRN) is a growth factor implicated in neurodegenerative diseases, including AD and PSP. AZP2006, a synthetic compound, targets tauopathies by stabilizing PGRN levels and reducing tau aggregation and neuroinflammation. Objective: Evaluate the safety, tolerability, and pharmacokinetics of AZP2006. Methods: A first-in-Human phase 1 study comprised a single ascending dose (SAD) and a multiple ascending dose study (MAD). The SAD study included 64 healthy male volunteers and tested singles oral doses of 3 to 500 mg of AZP2006 free base equivalent or placebo. In the MAD study, 24 healthy male volunteers were administered oral doses of 30, 60, and 120 mg per day of AZP2006 or placebo for 10 days. Results: No serious adverse events were observed. Clinical, biological, and electrocardiogram findings were non-relevant. Nineteen minor adverse events resolved before study completion. The safety profile indicated no specific risks. The multiple ascending dose study was halted, and the optional dose level of 180 mg was not performed due to high levels of M2 metabolite in plasma that necessitated additional preclinical evaluation of M2. Both AZP2006 and its M2 metabolite were quickly absorbed and widely distributed in tissues. Exposure increased more than proportionally with dose. Conclusions: AZP2006 had a favorable safety profile and was rapidly absorbed. Elevated M2 metabolite levels necessitated further studies to clarify excretion and metabolism mechanisms.


Subject(s)
Alzheimer Disease , Supranuclear Palsy, Progressive , Tauopathies , Humans , Male , Alzheimer Disease/drug therapy , Double-Blind Method , Healthy Volunteers , Dose-Response Relationship, Drug
2.
Int J Mol Sci ; 22(8)2021 Apr 09.
Article in English | MEDLINE | ID: mdl-33918621

ABSTRACT

Natural killer (NK) cells were originally described as cytolytic effector cells, but since then have been recognized to possess regulatory functions on immune responses. Chemokines locate NK cells throughout the body in homeostatic and pathological conditions. They may also directly stimulate immune cells. CCL18 is a constitutive and inducible chemokine involved in allergic diseases. The aim of this study was to evaluate CCL18's effect on NK cells from allergic and nonallergic donors in terms of both chemotactic and immune effects. Results showed that CCL18 was able to induce migration of NK cells from nonallergic donors in a G-protein-dependent manner, suggesting the involvement of a classical chemokine receptor from the family of seven-transmembrane domain G-protein-coupled receptors. In contrast, NK cells from allergic patients were unresponsive. Similarly, CCL18 was able to induce NK cell cytotoxicity only in nonallergic subjects. Purified NK cells did not express CCR8, one of the receptors described to be involved in CCL18 functions. Finally, the defect in CCL18 response by NK cells from allergic patients was unrelated to a defect in CCL18 binding to NK cells. Overall, our results suggest that some NK cell functions may be defective in allergic diseases.


Subject(s)
Chemokines, CC/metabolism , Hypersensitivity/immunology , Hypersensitivity/metabolism , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Biomarkers , Case-Control Studies , Chemotaxis/immunology , Cytokines/biosynthesis , Cytotoxicity, Immunologic , GTP-Binding Proteins/metabolism , Humans
3.
ACS Chem Neurosci ; 6(4): 559-69, 2015 Apr 15.
Article in English | MEDLINE | ID: mdl-25611616

ABSTRACT

The amyloid precursor protein (APP) plays a central role in Alzheimer's disease (AD). Preventing deregulated APP processing by inhibiting amyloidogenic processing of carboxy-terminal fragments (APP-CTFs), and reducing the toxic effect of amyloid beta (Aß) peptides remain an effective therapeutic strategy. We report the design of piperazine-containing compounds derived from chloroquine structure and evaluation of their effects on APP metabolism and ability to modulate the processing of APP-CTF and the production of Aß peptide. Compounds which retained alkaline properties and high affinity for acidic cell compartments were the most effective. The present study demonstrates that (1) the amino side chain of chloroquine can be efficiently substituted by a bis(alkylamino)piperazine chain, (2) the quinoline nucleus can be replaced by a benzyl or a benzimidazole moiety, and (3) pharmacomodulation of the chemical structure allows the redirection of APP metabolism toward a decrease of Aß peptide release, and increased stability of APP-CTFs and amyloid intracellular fragment. Moreover, the benzimidazole compound 29 increases APP-CTFs in vivo and shows promising activity by the oral route. Together, this family of compounds retains a lysosomotropic activity which inhibits lysosome-related Aß production, and is likely to be beneficial for therapeutic applications in AD.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Chloroquine/analogs & derivatives , Neuroprotective Agents/chemistry , Quinolines/chemistry , Amyloid beta-Peptides/metabolism , Animals , Blotting, Western , Cell Death/drug effects , Cell Line, Tumor , Chloroquine/chemistry , Chloroquine/pharmacology , Drug Design , Female , Frontal Lobe/drug effects , Frontal Lobe/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Mice, Inbred C57BL , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Neuroprotective Agents/pharmacology , Peptide Fragments/metabolism , Protein Stability/drug effects , Quinolines/pharmacology , Water/chemistry
4.
PLoS One ; 9(4): e94492, 2014.
Article in English | MEDLINE | ID: mdl-24727794

ABSTRACT

Eosinophils are potent inflammatory cells with numerous immune functions, including antigen presentation and exacerbation of inflammatory responses through their capacity to release a range of largely preformed cytokines and lipid mediators. Thus, timely regulation of eosinophil activation and apoptosis is crucial to develop beneficial immune response and to avoid tissue damage and induce resolution of inflammation. Natural Killer (NK) cells have been reported to influence innate and adaptive immune responses by multiple mechanisms including cytotoxicity against other immune cells. In this study, we analyzed the effect of the interaction between NK cells and eosinophils. Co-culture experiments revealed that human NK cells could trigger autologous eosinophil activation, as shown by up-regulation of CD69 and down-regulation of CD62L, as well as degranulation, evidenced by increased CD63 surface expression, secretion of eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN). Moreover, NK cells significantly and dose dependently increased eosinophil apoptosis as shown by annexin V and propidium iodide (PI) staining. Direct contact was necessary for eosinophil degranulation and apoptosis. Increased expression of phosphorylated extracellular signal-regulated kinase (ERK) in cocultured eosinophils and inhibition of eosinophil CD63 expression by pharmacologic inhibitors suggest that MAPK and PI3K pathways are involved in NK cell-induced eosinophil degranulation. Finally, we showed that NK cells increased reactive oxygen species (ROS) expression by eosinophils in co-culture and that mitochondrial inhibitors (rotenone and antimycin) partially diminished NK cell-induced eosinophil apoptosis, suggesting the implication of mitochondrial ROS in NK cell-induced eosinophil apoptosis. Pan-caspase inhibitor (ZVAD-FMK) only slightly decreased eosinophil apoptosis in coculture. Altogether, our results suggest that NK cells regulate eosinophil functions by inducing their activation and their apoptosis.


Subject(s)
Apoptosis , Eosinophils/cytology , Killer Cells, Natural/cytology , Adult , Apoptosis/drug effects , Cell Communication/drug effects , Cell Degranulation/drug effects , Electron Transport/drug effects , Eosinophil Cationic Protein/metabolism , Eosinophil-Derived Neurotoxin/metabolism , Eosinophils/drug effects , Eosinophils/enzymology , Eosinophils/physiology , Formaldehyde/pharmacology , Humans , Killer Cells, Natural/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Mitogen-Activated Protein Kinases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Polymers/pharmacology , Reactive Oxygen Species/metabolism , Solubility
5.
PLoS One ; 4(12): e8291, 2009 Dec 14.
Article in English | MEDLINE | ID: mdl-20011519

ABSTRACT

BACKGROUND: The development of mucosal vaccines is crucial to efficiently control infectious agents for which mucosae are the primary site of entry. Major drawbacks of these protective strategies are the lack of effective mucosal adjuvant. Synthetic oligodeoxynucleotides that contain several unmethylated cytosine-guanine dinucleotide (CpG-ODN) motifs are now recognized as promising adjuvants displaying mucosal adjuvant activity through direct activation of TLR9-expressing cells. However, little is known about the efficacy of these molecules in stimulating the intestinal immune system in neonates. METHODOLOGY/PRINCIPAL FINDINGS: First, newborn mice received CpG-ODN orally, and the intestinal cytokine and chemokine response was measured. We observed that oral administration of CpG-ODN induces CXC and CC chemokine responses and a cellular infiltration in the intestine of neonates as detected by immunohistochemistry. We next compared the efficiency of the oral route to intraperitoneal administration in stimulating the intestinal immune responses of both adults and neonates. Neonates were more responsive to TLR9-stimulation than adults whatever the CpG-ODN administration route. Their intestinal epithelial cells (IECs) indirectly responded to TLR9 stimulation and contributed to the CXC chemokine response, whereas other TLR9-bearing cells of the lamina-propria produced CC chemokines and Th1-type cytokines. Moreover, we showed that the intestine of adult exhibited a significantly higher level of IL10 at homeostasis than neonates, which might be responsible for the unresponsiveness to TLR9-stimulation, as confirmed by our findings in IL10-deficient mice. CONCLUSIONS/SIGNIFICANCE: This is the first report that deciphers the role played by CpG-ODN in the intestine of neonates. This work clearly demonstrates that an intraperitoneal administration of CpG-ODN is more efficient in neonates than in adults to stimulate an intestinal chemokine response due to their lower IL-10 intestinal level. In addition we report the efficiency of the oral route at inducing intestinal chemokine responses in neonate that might be taken into consideration for further vaccine development against neonatal diseases.


Subject(s)
Immunity/drug effects , Intestines/drug effects , Intestines/immunology , Oligodeoxyribonucleotides/pharmacology , Administration, Oral , Aging/drug effects , Animals , Animals, Newborn , Cell Movement/drug effects , Cell Separation , Chemokines/metabolism , Enterocytes/cytology , Enterocytes/drug effects , Female , Inflammation/pathology , Injections, Intraperitoneal , Interleukin-10/metabolism , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Lymph Nodes/drug effects , Lymph Nodes/pathology , Mice , Mice, Inbred C57BL , Oligodeoxyribonucleotides/administration & dosage , Rats , Th1 Cells/drug effects , Th1 Cells/immunology
6.
J Infect Dis ; 193(10): 1400-7, 2006 May 15.
Article in English | MEDLINE | ID: mdl-16619188

ABSTRACT

BACKGROUND: Neonates are particularly vulnerable to infections, in part because of the incomplete development of their immune system. Recent advances in immunostimulatory treatments based on conserved microbial components led us to assess the potential of oligodeoxynucleotides (ODNs) for decreasing the sensitivity of neonates to Cryptosporidium parvum infection. METHODS: Neonate mice were treated orally or intraperitoneally (ip) with CpG ODNs or non-CpG ODNs 24 h before C. parvum infection, and parasite load and cytokine up-regulation were evaluated. RESULTS: CpG ODN 1668 and non-CpG ODN 1668 administered orally, as well as CpG ODN 1668 administered ip, induced an 80%-95% decrease in intestinal parasite load 6 days after infection. Intraperitoneal and oral pretreatment with CpG ODN 1668 led to a strong initial up-regulation of cytokines and CD69 messenger RNA in the intestine and a decrease in parasite load by a Toll-like receptor 9 (TLR9)-dependent mechanism. By contrast, oral administration of non-CpG ODN 1668 decreased parasite load by a TLR9-independent mechanism. CONCLUSION: The control of neonatal C. parvum infection by ip or oral administration of ODNs is feasible by 2 different mechanisms: (1) the well-known interaction involving CpG/TLR9, leading to the production of cytokines and lymphocyte activation, and (2) a new unknown mechanism that is independent of TLR9 and effective orally.


Subject(s)
Adjuvants, Immunologic/pharmacology , Cryptosporidium parvum/drug effects , Oligodeoxyribonucleotides/pharmacology , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/therapeutic use , Administration, Oral , Animals , Animals, Newborn , Cryptosporidiosis/drug therapy , Cryptosporidium parvum/pathogenicity , Disease Models, Animal , Drug Administration Schedule , Female , Humans , Injections, Intraperitoneal , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Oligodeoxyribonucleotides/administration & dosage , Oligodeoxyribonucleotides/therapeutic use , Parasitic Sensitivity Tests , Polymerase Chain Reaction , RNA, Protozoan/analysis , Specific Pathogen-Free Organisms
7.
Infect Immun ; 72(6): 3634-7, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15155674

ABSTRACT

Numerous inflammatory cells are recruited in response to Cryptosporidium parvum infection. These cells include interferon gamma-producing T lymphocytes, which are of major importance for the resolution of infection. Here, we show that beta7 integrin is not essential for the control of infection in mice but that beta7-deficient neonatal mice are more susceptible during the early stages of infection.


Subject(s)
Cryptosporidiosis/immunology , Cryptosporidium parvum/pathogenicity , Integrin beta Chains/genetics , Integrin beta Chains/metabolism , Animals , Animals, Newborn , Cattle , Cryptosporidiosis/parasitology , Cryptosporidiosis/physiopathology , Disease Susceptibility , Humans , Ileum/immunology , Ileum/parasitology , Mice , Mice, Inbred C57BL , T-Lymphocytes/immunology , Time Factors
8.
Infect Immun ; 72(4): 2131-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15039335

ABSTRACT

The control of Listeria monocytogenes infection depends on the rapid activation of the innate immune system, likely through Toll-like receptors (TLR), since mice deficient for the common adapter protein of TLR signaling, myeloid differentiation factor 88 (MyD88), succumb to Listeria infection. In order to test whether TLR2 is involved in the control of infections, we compared the host response in TLR2-deficient mice with that in wild-type mice. Here we show that TLR2-deficient mice are more susceptible to systemic infection by Listeria than are wild-type mice, with a reduced survival rate, increased bacterial burden in the liver, and abundant and larger hepatic microabscesses containing increased numbers of neutrophils. The production of tumor necrosis factor, interleukin-12, and nitric oxide and the expression of the costimulatory molecules CD40 and CD86, which are necessary for the control of infection, were reduced in TLR2-deficient macrophages and dendritic cells stimulated by Listeria and were almost abolished in the absence of MyD88, coincident with the high susceptibility of MyD88-deficient mice to in vivo infection. Therefore, the present data demonstrate a role for TLR2 in the control of Listeria infection, but other MyD88-dependent signals may contribute to host resistance.


Subject(s)
Listeria monocytogenes , Listeriosis/immunology , Membrane Glycoproteins/metabolism , Receptors, Cell Surface/metabolism , Adaptor Proteins, Signal Transducing , Animals , Antigens, Differentiation/metabolism , Cells, Cultured , Dendritic Cells/immunology , Dendritic Cells/microbiology , Listeria monocytogenes/immunology , Listeriosis/microbiology , Listeriosis/mortality , Liver/microbiology , Liver Abscess/immunology , Liver Abscess/microbiology , Macrophages/immunology , Macrophages/microbiology , Membrane Glycoproteins/genetics , Mice , Mice, Inbred C57BL , Myeloid Differentiation Factor 88 , Receptors, Cell Surface/genetics , Receptors, Immunologic/metabolism , Toll-Like Receptor 2 , Toll-Like Receptors
SELECTION OF CITATIONS
SEARCH DETAIL
...